FERD3L

Across TCGA pan-cancer cohorts, FERD3L Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FERD3L data layer compared with 16 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher FERD3L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FERD3L expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

LUSC, SKCM, and LUAD are the cancer types where FERD3L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.295	0.737	<.001	12	view →
SKCM	DFS	Median	II,III,IV	0.989	0.538	.011	11	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
BLCA	OS	Median	III,IV	0.253	0.656	.011	9	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
UCEC	OS	Median	All	0.961	0.652	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FERD3L–LUSC (OS)

Open the LUSC breakdown →